Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Seeking Alpha
Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 million public offering and an untapped $125 million loan facility extend KYTX's cash runway into 2027, enabling continued pipeline progress. The market currently values KYTX only slightly above cash, underappreciating miv-cel's commercial potential, especially if proof-of-concept approval is achieved. LumerB/iStock via Getty Images Topline Summary I've only had one look at Kyverna Therapeutics ( KYTX ), and at that time a year ago, I had some reservations about their timelines and cash burn, ultimately landing on a "Hold" sentiment at the This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.MarketBeat
- Kyverna Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]Seeking Alpha
KYTX
Earnings
- 11/12/25 - Beat
KYTX
Sec Filings
- 12/18/25 - Form 8-K
- 12/18/25 - Form 424B5
- 12/17/25 - Form 4
- KYTX's page on the SEC website